Literature DB >> 15009222

Autosomal dominant lateral temporal epilepsy: two families with novel mutations in the LGI1 gene.

Peter Hedera1, Bassel Abou-Khalil, Amy E Crunk, Kelly A Taylor, Jonathan L Haines, James S Sutcliffe.   

Abstract

PURPOSE: Mutations in the leucine rich, glioma inactivated gene (LGI1) were recently described in a small number of families with autosomal dominant lateral temporal epilepsy (ADLTE). ADLTE is characterized by partial seizures with symptoms suggestive of a lateral temporal onset, including frequent auditory aura. Here we report the results of clinical and genetic analyses of two newly identified families with ADTLE.
METHODS: We identified two families whose seizure semiology was suggestive of ADLTE. Evaluation included a detailed history and neurologic examination, as well as collection of DNA. The coding sequence of the LGI1 gene from affected subjects from both families was analyzed for evidence of mutation.
RESULTS: Each patient had a history of partial seizures, often with secondary generalization earlier in the course. Auditory aura was reported by approximately two thirds of affected patients in each pedigree. Novel mutations in LGI1 were detected in both families. A heterozygous single-nucleotide deletion at position 329 (del 329C) was detected in affected individuals from one family, whereas patients from the second family had a nonsynonymous variation, corresponding to C435G.
CONCLUSIONS: We identified two novel mutations in the LGI1 gene. The phenotype of these two families was similar to that of other kindreds with ADLTE, as auditory aura was absent in one third of affected individuals. Our results further support that LGI1 mutations should be considered in patients with a history of partial seizures if the semiology of seizures is consistent with the onset in the lateral temporal lobe.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009222     DOI: 10.1111/j.0013-9580.2004.47203.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

1.  A method for estimating penetrance from families sampled for linkage analysis.

Authors:  Yuanjia Wang; Ruth Ottman; Daniel Rabinowitz
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

Review 2.  LGI1: a gene involved in epileptogenesis and glioma progression?

Authors:  W Gu; E Brodtkorb; T Piepoli; G Finocchiaro; O K Steinlein
Journal:  Neurogenetics       Date:  2005-04-13       Impact factor: 2.660

3.  Domain-dependent clustering and genotype-phenotype analysis of LGI1 mutations in ADPEAF.

Authors:  Yuan-Yuan Ho; Iuliana Ionita-Laza; Ruth Ottman
Journal:  Neurology       Date:  2012-02-08       Impact factor: 9.910

4.  Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1.

Authors:  Tiziana Piepoli; Cemile Jakupoglu; Wenli Gu; Elena Lualdi; Blanca Suarez-Merino; Pietro L Poliani; Maria Grazia Cattaneo; Barbara Ortino; Dorota Goplen; Jian Wang; Rosa Mola; Francesca Inverardi; Carolina Frassoni; Rolf Bjerkvig; Ortrud Steinlein; Lucia M Vicentini; Oliver Brüstle; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2006-03-02       Impact factor: 12.300

5.  Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features.

Authors:  Michael J Rosanoff; Ruth Ottman
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

6.  Genetics of temporal lobe epilepsy: a review.

Authors:  Annick Salzmann; Alain Malafosse
Journal:  Epilepsy Res Treat       Date:  2012-02-19

7.  Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22.

Authors:  Atsushi Yamagata; Yuri Miyazaki; Norihiko Yokoi; Hideki Shigematsu; Yusuke Sato; Sakurako Goto-Ito; Asami Maeda; Teppei Goto; Makoto Sanbo; Masumi Hirabayashi; Mikako Shirouzu; Yuko Fukata; Masaki Fukata; Shuya Fukai
Journal:  Nat Commun       Date:  2018-04-18       Impact factor: 14.919

8.  Neocortical temporal lobe epilepsy.

Authors:  Eduard Bercovici; Balagobal Santosh Kumar; Seyed M Mirsattari
Journal:  Epilepsy Res Treat       Date:  2012-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.